Capricor Receives CRL for Deramiocel BLA After FDA Cites Irreparable Data Integrity Violations in HOPE-3
FDA issues CRL for Capricor's deramiocel BLA, citing irreparable data integrity violations in Study HOPE-3 that no post-hoc amendment could resolve.


Data integrity failures in a single pivotal study have been sufficient to collapse Capricor Therapeutics' entire Biologics License Application for deramiocel, an allogeneic cardiosphere-derived cell therapy for Duchenne muscular dystrophy, a outcome that carries direct implications for QA directors overseeing rare disease programs where post-hoc remediation is rarely an option.
On November 20, 2026, the FDA's Office of Therapeutic Products (OTP), CBER issued a Complete Response Letter citing serious data integrity violations in the conduct of Study HOPE-3. The agency determined those violations cannot be remediated after the fact, effectively foreclosing any path to approval based on the current dataset. The decision followed a comprehensive multidisciplinary review of the BLA, inspectional findings, and a public advisory committee meeting held July 29, 2026, before the Cellular, Tissue, and Gene Therapy Advisory Committee (CTGTAC).
Following the CTGTAC meeting, Capricor submitted a major amendment introducing 24-month open-label extension data from Study HOPE-3-OLE and pivoted its proposed indication from cardiomyopathy to upper limb impairment in DMD patients. FDA reviewed the totality of evidence, including the amended submission, and concluded the evidentiary standard for approval remained unmet. The indication change did not insulate the application from the underlying study-conduct deficiencies flagged during inspection.
For regulatory affairs leads, the case reinforces a principle embedded in 21 CFR Part 211 and ICH Q10 quality system expectations: data integrity is not a correctable deficiency once a BLA is under review. Inspectional findings that surface violations in study conduct, particularly in cell and gene therapy programs operating under CBER's biologics framework, carry the same evidentiary weight as clinical outcome data. Strong patient advocacy, unmet medical need, and supplemental open-label data did not alter that calculus.
FDA's statement explicitly noted that upholding evidentiary standards is the mechanism by which the agency protects rare disease patients from interventions whose benefit-risk profile has not been sufficiently established, a framing that signals the agency will not apply a lower data integrity threshold in rare disease contexts regardless of public pressure.
Capricor's next steps, including whether the company will pursue a resubmission strategy or initiate a new study to generate a clean dataset, will determine the timeline for any future deramiocel review.
Source: U.S. Food and Drug Administration, What's New in Biologics (FDA.gov), November 20, 2026.

Reporting on the science, business and regulation shaping the pharmaceutical industry.
More from Pharma News
All stories →
India Positions Itself as Global Diabetes R&D Hub Targeting GLP-1 and Microbiome Therapies

Capricor Therapeutics Receives FDA Complete Response Letter for Deramiocel

Discussion